Home Cart Sign in  
Chemical Structure| 606143-52-6 Chemical Structure| 606143-52-6

Structure of Selumetinib
CAS No.: 606143-52-6

Chemical Structure| 606143-52-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Selumetinib (AZD6244) is a selective, non-ATP-competitive oral MEK1/2 inhibitor with an IC50 of 14 nM for MEK1, and it inhibits ERK1/2 phosphorylation.

Synonyms: AZD6244; ARRY-142886; ARRY886

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Raúl Garde Casasnovas ;

Abstract: Resumen: In this thesis three calibration approaches applied to high resolution continuum source graphite furnace atomic/molecular absorption spectrometry (HR CS GF AAS/MAS) have been studied. The advantages of multi-energy calibration for Br determination using Ca by monitoring the molecule CaBr have been assessed and compared with a similar approach developed during this study called multi energy ratios (MER). MER Data treatment does not require linear regression, and a dispersion of ratios between sample and sample+spike is calculated, this relationship is equivalent to the slope calculated in MEC. Since the basis mathematical relationship of this methodology is not linear, accuracy and precision of the method depend on the relative amounts of sample and amount of spike added. Better results were observed if the ratios/slope between signals of sample and saple+spike were near 0.5. results of MEC and MER were compared at two transitions of CaBr, Χ2Σ → A2Π (0,0) y Χ2Σ → B2 Σ(1,0), showing that for similar molecular transition sensitivities, MER is a more reliable strategy. If the number of transitions is high and with different sensitivities, MEC provides better precision. Besides, a method for the calculus of the limits of detection and quantification using MER, which allows to identify if the lines have the sensitivity needed for its application. Despite a wavy background around 625 nm, and the presence of an unknown molecule, the measurements of a certified reference material QC3060 showed accurate results for Br. The capabilities of a machine learning algorithm (ML) for the determination of halogen proportions in active pharmaceutical ingredients (API) by means of a modular simultaneous echelle spectrograph (MOSES) prototype, capable of increase the spectral window 100 times the values found in commercial continuum source instruments, coupled to a contrAA800G. Due to the univariate nature of the tree boosting algorithm, three models for F, Cl and Br each were calculated. Br model showed a bad performance, and it was decided to calculate its concentration through the remaining fraction. Validation parameters (Venetian blinds with ten splits and root mean square error of calibration, RMSEC) along with the four CRM proportions, which have variable quantities of the three halogens of interest, have shown the correct performance of the ML model. Additionally, MER was applied for the determination of F in these samples,.with errors under 5%. Afterwards, according to the proportions provided by the XGboost model and F concentration determined using MER, Br and Cl concentrations were determined, with errors under 10%. In this study, nanoparticles (NPs) and core-shell nanoparticles (SNPs) have been analyzed in order to identify between the atomization processes of NPs and ions of Cu, Pt, SiO2, Au and Ag by means of HR CS GF AAS. Thus, a parameter called tdelay (atomization delay) was used, Absorbance spectra of NPs and ions of these elements did not show differences at any of the ramps studied. However, Au and Ag did show differences in their tedlay, calculated using a peak fit strategy. Au showed a unimodal signal for NPs following a Voigt profile,on the other hand, Au ions presented from one to two peaks, depending on the state of the tube. Ag, on the contrary, showed a complex signal for every specie analyzed, adjusting better for three Gaussian peaks. The analysis of mixtures of Au showed that only a few mixtures with high differing masses presented a double peak. The rest of the mixtures appear as a unimodal signal. In both cases, size was estimated comparing their tdelay with pure AuNPs. Results show variable errors but iut seems that mixtures with significantly differing sizes provided size values closer to the expected ones. No mixture of AgNPs showed a bimodal peak. Hence, size was compared to the average size and average volume of NPs. Ag results presented lower error, except for a mixture with -19%, all mixtures showed less than 10% error in size relative to the average size. CSNP measurements showed that size estimated using the shell if it is comprised of Au and Ag, provided similar results to the overall size of the CSNPS. Core size characterization, on the other hand, showed errors around 20%. CSNPs smaller of 20 nm presented a high error and imprecision. Lastly, the effect of the presence of silica in the structure of CSNPs with Au was assessed. In Au@SiNPs, Au-core atomizes much later than expected according to previous experiments, with a different peak profile. Si@AuNPs, Res660, Res800 and Res980, were analyzed to calculate the size of the Au structure (shell). However, these CSNPs are larger than the standards measured, and results were calculated by extrapolation. Errors between -20 and 20% were achieved, relatively good values were achieved for extrapolated data. Finally, Si-core was estimated in Si@AuNPs through the difference of the total volume of the CSNP (estimated experimentally sizing the Au-shell) and the volume of atoms of the shell occupied (volume per concentration of Au in the sample including the particle number, provided by the manufacturer).

Purchased from AmBeed:

Alternative Products

Product Details of Selumetinib

CAS No. :606143-52-6
Formula : C17H15BrClFN4O3
M.W : 457.68
SMILES Code : O=C(C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C3N=CN(C)C3=C1)NOCCO
Synonyms :
AZD6244; ARRY-142886; ARRY886
MDL No. :MFCD11977472
InChI Key :CYOHGALHFOKKQC-UHFFFAOYSA-N
Pubchem ID :10127622

Safety of Selumetinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of Selumetinib

MAPK

Isoform Comparison

Biological Activity

Target
  • MEK2

    MEK2, Kd:530 nM

  • MEK1

    MEK1, IC50:14 nM

    MEK1, Kd:99 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
NF1-mutant NF95.11b neuro fibroma cells 1 μM 48 h To test if PRC2 inactivation is sufficient for selumetinib resistance, results showed that PRC2 inactivation inhibited Schwann cell differentiation marker expression and attenuated selumetinib responses. PMC10786885
Human monocyte-derived dendritic cells (mDC) 1 μM 48 h Selumetinib increased the expression of activation markers CD80, CD83, CD86, and HLA-DR on mDCs. PMC5557252
CT26 murine colon adenocarcinoma cells 0.123 μM 48 h Selumetinib increased the expression of H2-Kd class-I MHC proteins and decreased PD-L1 expression in CT26 cells. PMC5557252
Human peripheral blood mononuclear cells (PBMC) 5.8 nM (IC50) 72 h Selumetinib inhibited T-cell activation and reduced IL-2 secretion. PMC5557252
A172 cells 10 nM 24 h To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. PMC10318069
U251MG cells 10 nM 24 h To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. PMC10318069
Primary astrocytes 1 μM 48 h To study the effect of Selumetinib on the activity of primary astrocytes, the results showed that Selumetinib did not affect cell activity. PMC8922810
SUM149 0.1 μM and 1 μM 48 h To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. PMC4674314
MDA-MB-231 0.1 μM and 1 μM 48 h To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. PMC4674314
SUM149 0.001, 0.01, 0.1, 1, or 10 μM 72 h To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. PMC4674314
MDA-MB-231 0.001, 0.01, 0.1, 1, or 10 μM 72 h To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. PMC4674314
NF1-deficient human Schwann cells 10-100 nM 48 h To evaluate the cytotoxic effect of CQ on NF1-deficient human Schwann cells, results showed that CQ significantly reduced the viability of NF1/C0//C0 cells. PMC11887668
NF1-deficient Drosophila cells 1-10 µM 48 h To evaluate the cytotoxic effect of CQ on NF1-deficient cells, results showed that CQ significantly reduced the viability of dNF1-KO cells. PMC11887668
A549 cells 1 μM 24 hours To study the effect of MEK inhibitors on KRAS-mutant lung cancer cells, it was found that MEK inhibitors including GDC-0623 enhanced HGF- and EGF-induced AKT phosphorylation. PMC5065770

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice JW23.3 MPNST allograft model Oral 25 mg/kg Twice daily for 21 days To test the in vivo efficacy of Selumetinib, results showed that Selumetinib significantly inhibited the growth of MPNST allografts. PMC10786885
Mice CT26 murine colorectal cancer model Oral 25 mg/kg Twice daily for 8 days Selumetinib reduced CD11b+Ly6G+ granulocytic cells in the tumor microenvironment, increased the frequency of CD11b+Ly6C+MHCII+ intermediate differentiating monocytes, and decreased the expression of Cox-2 and Arg1. PMC5557252
NOD/SCID mice GBM xenograft model Intraperitoneal injection 50 mg/kg Daily until the end of the experiment To evaluate the inhibitory effect of Selumetinib on GBM tumor growth. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM tumor growth and prolonged the survival of mice. PMC10318069
Mice Intracerebral hemorrhage model In situ injection 5 mg/kg Single injection, lasting 10 minutes To study the therapeutic effect of Selumetinib on mice with intracerebral hemorrhage model, the results showed that Selumetinib improved the pathological indices and prognosis after intracerebral hemorrhage. PMC8922810
Female athymic nude mice Triple-negative breast cancer xenograft model Oral 50 mg/kg Daily for 3 weeks To evaluate the inhibitory effect of Selumetinib on lung metastasis, results showed that Selumetinib significantly reduced the incidence of lung metastasis. PMC4674314
Mice NF1-deficient MPNST xenograft model Intraperitoneal injection 50 mg/kg Three times per week for 3 weeks To evaluate the inhibitory effect of CQ on NF1-deficient tumors, results showed that CQ significantly slowed tumor growth, and the effect was superior to Selumetinib. PMC11887668

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00085787 Advanced Cancer Phase 1 Completed - United States, Colorado ... More >> University of Colorado Cancer Center, Anschutz Cancer Center Aurora, Colorado, United States, 80010 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT00780676 Breast Cancer Phase 2 Terminated(Closed early for fu... More >>tility.) Less << - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02546661 Muscle Invasive Bladder Cancer Phase 1 Recruiting March 27, 2020 -
NCT00780676 - Terminated(Closed early for fu... More >>tility.) Less << - -
NCT02179671 Locally Advanced or Metastatic... More >> Non-Small-Cell Lung Cancer (Stage IIIB-IV) Less << Phase 2 Completed - United States, Arizona ... More >> Research Site Goodyear, Arizona, United States United States, District of Columbia Research Site Washington, District of Columbia, United States United States, Georgia Research Site Augusta, Georgia, United States Research Site Marietta, Georgia, United States United States, Kentucky Research Site Ashland, Kentucky, United States United States, Missouri Research Site St Louis, Missouri, United States United States, New York Research Site Mineola, New York, United States United States, North Carolina Research Site Huntersville, North Carolina, United States United States, Washington Research Site Spokane, Washington, United States Research Site Tacoma, Washington, United States Less <<
NCT01229150 Non Small Cell Lung Carcinoma Phase 2 Completed - United States, California ... More >> University of California, Davis Davis, California, United States, 95616 University of Southern California Health Sciences Campus Los Angeles, California, United States, 90033 City of Hope Medical Group South Pasadena, California, United States, 91030 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00936221 Melanoma Phase 2 Completed - -
NCT01229150 - Completed - -
NCT00936221 - Completed - -
NCT01134601 Non-Metastatic Adenocarcinoma ... More >>of the Rectum Less << Phase 1 Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01160926 Rectal Cancer Phase 1 Terminated(2 DLTs had been rep... More >>orted from first 4 patients on lowest possible dose cohort.) Less << September 2016 United Kingdom ... More >> The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Less <<
NCT01750281 Locally Advanced or Metastatic... More >> Non Small Cell Lung Cancer Stage IIIb - IV Less << Phase 2 Active, not recruiting December 31, 2018 -
NCT02143466 Advanced Non Small Cell Lung C... More >>ancer Less << Phase 1 Recruiting December 30, 2019 -
NCT00866177 Recurrent Melanoma ... More >> Stage III Skin Melanoma Stage IV Skin Melanoma Less << Phase 2 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01287130 Colonic Neoplasms ... More >> Cancer of the Colon Colon Cancer Colon Neoplasms Colonic Cancer Less << Phase 1 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00710515 Melanoma|Malignant Melanoma PHASE1 COMPLETED 2025-06-10 Research Site, Amsterdam, Neth... More >>erlands|Research Site, Maastricht, Netherlands|Research Site, Glasgow, United Kingdom|Research Site, Headington, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom Less <<
NCT01750281 - Active, not recruiting - -
NCT01143402 - Completed - -
NCT00866177 - Completed - -
NCT01166126 Mucosal Melanoma ... More >> Recurrent Melanoma Stage IV Melanoma Less << Phase 2 Terminated - United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT00890825 - Completed - -
NCT01166126 - Terminated - -
NCT00514761 Metastatic Colorectal Cancer Phase 2 Completed - Brazil ... More >> Research Site Goiania, Brazil Research Site Rio de Janeiro, Brazil Research Site Sao Paulo, Brazil Less <<
NCT01256359 Melanoma Phase 2 Active, not recruiting December 2018 United Kingdom ... More >> Churchill Hospital Oxford, Oxfordshire, United Kingdom, OX3 7LJ Less <<
NCT00372944 Pancreatic Cancer Phase 2 Completed - United States, California ... More >> Research Site Alhambra, California, United States Research Site Bakersfield, California, United States Research Site Palm Springs, California, United States Research Site Santa Maria, California, United States United States, Florida Research Site Orlando, Florida, United States United States, Maryland Research Site Chevy Chase, Maryland, United States United States, Michigan Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Texas Research Site Temple, Texas, United States United States, Washington Research Site Seattle, Washington, United States Australia Research Site Heidelburg, Australia Bulgaria Research Site Plovdiv, Bulgaria Research Site Sofia, Bulgaria Research Site Varna, Bulgaria Hungary Research Site Budapest, Hungary Romania Research Site Cluj-Napoca, Romania Less <<
NCT00890825 Non Small Cell Lung Cancer Phase 2 Completed - -
NCT00600496 Breast Cancer ... More >> Breast Neoplasms Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer Less << Phase 1 Active, not recruiting December 31, 2018 United States, Michigan ... More >> Research Site Detroit, Michigan, United States, 48201 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Houston, Texas, United States, 77030 Less <<
NCT00372788 Non-small Cell Lung Cancer Phase 2 Completed - United States, California ... More >> Research Site Los Angeles, California, United States United States, Michigan Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States Bulgaria Research Site Plovdiv, Bulgaria Research Site Sofia, Bulgaria Research Site Varna, Bulgaria Romania Research Site Cluj-Napoca, Romania Less <<
NCT01143402 Iris Melanoma ... More >> Medium/Large Size Posterior Uveal Melanoma Ocular Melanoma With Extraocular Extension Recurrent Uveal Melanoma Small Size Posterior Uveal Melanoma Stage IV Uveal Melanoma Less << Phase 2 Completed - -
NCT01658943 - Completed - -
NCT01021748 Locally Advanced or Metastatic... More >> Solid Tumors Less << Phase 1 Completed - -
NCT00970359 - Completed - -
NCT01658943 Pancreatic Acinar Cell Carcino... More >>ma Pancreatic Ductal Adenocarcinoma Recurrent Pancreatic Carcinoma Stage IV Pancreatic Cancer Less << Phase 2 Completed - -
NCT01313039 - Completed - -
NCT00970359 Thyroid Cancer Not Applicable Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01021748 - Completed - -
NCT00338130 Melanoma Phase 2 Completed - -
NCT01859182 Adenocarcinoma of the Gallblad... More >>der Adenocarcinoma With Squamous Metaplasia of the Gallbladder Adult Primary Cholangiocellular Carcinoma Advanced Adult Primary Liver Cancer Cholangiocarcinoma of the Extrahepatic Bile Duct Localized Unresectable Adult Primary Liver Cancer Metastatic Extrahepatic Bile Duct Cancer Recurrent Adult Primary Liver Cancer Recurrent Extrahepatic Bile Duct Cancer Stage II Gallbladder Cancer Stage IIIA Gallbladder Cancer Stage IIIB Gallbladder Cancer Stage IVA Gallbladder Cancer Stage IVB Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Less << Phase 2 Withdrawn - -
NCT01160718 Breast Cancer Phase 2 Completed - Belgium ... More >> Universitair Ziekenhuis Gent Ghent, Belgium, B-9000 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Switzerland Kantonsspital Aarau Aarau, Switzerland, CH-5001 Kantonsspital Baden Baden, Switzerland, CH-5404 Universitaetsspital-Basel Basel, Switzerland, CH-4031 Inselspital Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2501 Kantonsspital Graubuenden Chur, Switzerland, CH-7000 Brustzentrum Thurgau at Kantonsspital Frauenfeld Frauenfeld, Switzerland, 8501 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Kantonsspital Luzern Luzerne, Switzerland, CH-6000 Oncology Institute of Southern Switzerland - Mendrisio Mendrisio, Switzerland, CH-6850 Hopital de Morges Morges, Switzerland, CH-1110 Kantonsspital - St. Gallen St. Gallen, Switzerland, CH-9007 Hopitaux Universitaires de Geneve Thonex-Geneve, Switzerland, CH-1226 Kantonsspital Winterthur Winterthur, Switzerland, CH-8400 City Hospital Triemli Zurich, Switzerland, CH-8063 Less <<
NCT01364051 Solid Neoplasm ... More >> Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << Phase 1 Active, not recruiting - United States, Florida ... More >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02685657 Triple Negative Breast Cancer Phase 2 Unknown - -
NCT01333475 Colorectal Neoplasms Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01313039 Breast Cancer Early Phase 1 Completed - United States, Florida ... More >> University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 Less <<
NCT02151084 Biliary Tract Carcinoma ... More >> Gallbladder Carcinoma Less << Phase 2 Completed - Canada, Ontario ... More >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT02337530 Non-Small Cell Lung Cancer Phase 2 Active, not recruiting December 31, 2018 Canada, Alberta ... More >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA - Abbotsford Centre Abbotsford, British Columbia, Canada, V2S 0C2 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, New Brunswick Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 Lakeridge Health Oshawa Oshawa, Ontario, Canada, L1G 2B9 Ottawa Hospital Research Institute Ottawa, Ontario, Canada, K1H 8L6 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec CHUM - Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Less <<
NCT01206140 Recurrent Adult Soft Tissue Sa... More >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Less << Phase 2 Completed - United States, California ... More >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 University of California Davis Phase 2 Consortium Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT03259633 NF type1 With Inoperable Plexi... More >>form Neurofibromas Less << APPROVED_FOR_MARKETING - Research Site, New Orleans, Lo... More >>uisiana, 12345, United States Less <<
NCT01206140 - Completed - -
NCT01333475 - Completed - -
NCT00604721 - Completed - -
NCT01217450 Recurrent Colon Cancer ... More >> Recurrent Rectal Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> National Cancer Institute Medicine Branch Bethesda, Maryland, United States, 20892 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Wisconsin Clinical Cancer Center Milwaukee, Wisconsin, United States, 53226 Less <<
NCT00463814 Tumor|Cancer PHASE1 ACTIVE_NOT_RECRUITING 2025-12-31 Research Site, Aurora, Colorad... More >>o, 80045, United States|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Utrecht, 3584 CX, Netherlands|Research Site, Sutton, SM2 5PT, United Kingdom Less <<
NCT01362803 Neurofibromatosis 1|Neurofibro... More >>matosis Type 1|NF1|Neurofibroma, Plexiform Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2032-01-01 Children's National Medical Ce... More >>nter, Washington, District of Columbia, 20010, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT01222689 Adenocarcinoma of the Pancreas... More >> Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Less << Phase 2 Completed - United States, California ... More >> UCSF-Mount Zion San Francisco, California, United States, 94115 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT00604721 Adult Primary Hepatocellular C... More >>arcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer Less << Phase 2 Completed - United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<
NCT01586624 Cancer Non Sm... More >>all Cell Lung Cancer Less << Phase 1 Active, not recruiting March 2019 United Kingdom ... More >> Cambridge Cancer Trials Centre (S4), Box 279, Addenbrooke's Hospital Hills Road, Cambridge, United Kingdom, CB2 0QQ The Christie NHS Foundation Trust Withington, Manchester, United Kingdom, M20 4BX Churchill Hospital Headington, Oxford, United Kingdom, OX3 7LJ The Freeman Hospital Newcastle, United Kingdom, NE7 7DN Less <<
NCT01222689 - Completed - -
NCT00551070 - Active, not recruiting - -
NCT00553332 - Completed - -
NCT00551070 Borderline Ovarian Epithelial ... More >>Tumor Low Grade Ovarian Serous Adenocarcinoma Primary Peritoneal Carcinoma Primary Peritoneal Low Grade Serous Adenocarcinoma Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor Less << Phase 2 Active, not recruiting - -
NCT02586987 Lung Cancer M... More >>elanoma Head and Neck Carcinoma Gastroesophageal Cancer Breast Cancer Pancreatic Adenocarcinoma Colorectal Cancer Biliary Tract Cancer Less << Phase 1 Active, not recruiting December 31, 2019 United States, Illinois ... More >> Research Site Chicago, Illinois, United States, 60637 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02215 United States, Nevada Research Site Las Vegas, Nevada, United States, 89169-3321 United States, New Jersey Research Site New Brunswick, New Jersey, United States, 8901 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Pennsylvania Research Site Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00553332 Liver and Intrahepatic Biliary... More >> Tract Cancer Recurrent Extrahepatic Bile Duct Cancer Unresectable Extrahepatic Bile Duct Cancer Less << Phase 2 Completed - United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Michigan University of Michigan Cancer Center (UMCC) Research Base Ann Arbor, Michigan, United States, 48109-0352 Wayne State University Detroit, Michigan, United States, 48202 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 Less <<
NCT01519427 Recurrent Melanoma ... More >> Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Less << Phase 2 Terminated(Study terminated du... More >>e to slow accrual) Less << - United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT01029418 Hepatocellular Carcinoma Phase 1 Phase 2 Terminated(The phase II portio... More >>n was not conducted due to funding issue.) Less << - Singapore ... More >> National University Hospital Singapore Singapore, Singapore, 119074 National Cancer Centre Singapore Singapore, Singapore, 169610 Less <<
NCT03649165 Neurofibromatosis Type 1 (NF1)... More >>-Related Plexiform Neurofibromas (PNs) Healthy Participants Less << Phase 1 Completed - United States, Maryland ... More >> Research Site Baltimore, Maryland, United States, 21225 Less <<
NCT02503358 Stage IIIB Non-Small Cell Lung... More >> Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << Phase 1 Recruiting September 1, 2019 United States, Oregon ... More >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Khaled A. Tolba    503-494-8666    tolba@ohsu.edu    Principal Investigator: Khaled A. Tolba Less <<
NCT01933932 Locally Advanced or Metastatic... More >> Non Small Cell Lung Cancer Stage IIIb - IV Less << Phase 3 Active, not recruiting December 31, 2018 -
NCT01519427 - Terminated(Study terminated du... More >>e to slow accrual) Less << - -
NCT01011933 - Completed - -
NCT01933932 - Active, not recruiting - -
NCT01605916 Neoplasms,|Metastatic Cancer,|... More >>Non-Small Cell Lung Cancer|Advanced Solid Malignancies Less << PHASE1 COMPLETED 2025-05-15 Research Site, Fukuoka-shi, Ja... More >>pan|Research Site, Kashiwa-shi, Japan|Research Site, Nagoya-shi, Japan Less <<
NCT01116271 Colorectal Cancer Phase 2 Completed - United States, California ... More >> Research Site Los Angeles, California, United States Research Site Palm Springs, California, United States United States, Colorado Research Site Aurora, Colorado, United States United States, Connecticut Research Site New Haven, Connecticut, United States United States, Delaware Research Site Newark, Delaware, United States United States, Florida Research Site Miami Beach, Florida, United States United States, New York Research Site New York, New York, United States United States, North Carolina Reserach Site Chapel Hill, North Carolina, United States Research Site Greenville, North Carolina, United States Research Site Washington, North Carolina, United States United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States United States, Washington Research Site Seattle, Washington, United States Less <<
NCT01089101 Low Grade Glioma ... More >> Recurrent Childhood Pilocytic Astrocytoma Recurrent Neurofibromatosis Type 1 Recurrent Visual Pathway Glioma Refractory Neurofibromatosis Type 1 Refractory Visual Pathway Glioma Less << Phase 1 Phase 2 Recruiting - United States, California ... More >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Girish Dhall    323-361-4629       Principal Investigator: Girish Dhall          Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Michelle Monje    650-721-5750       Principal Investigator: Michelle Monje          UCSF Medical Center-Mount Zion Active, not recruiting San Francisco, California, United States, 94115 UCSF Medical Center-Parnassus Recruiting San Francisco, California, United States, 94143 Contact: Anuradha Banerjee    877-827-3222       Sub-Investigator: Anuradha Banerjee          Sub-Investigator: Michael D. Prados          United States, Colorado Children's Hospital Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Kathleen M. Dorris    720-777-8314       Principal Investigator: Kathleen M. Dorris          United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Eugene I. Hwang    202-476-5046       Principal Investigator: Eugene I. Hwang          United States, Illinois Lurie Children's Hospital-Chicago Recruiting Chicago, Illinois, United States, 60611 Contact: Stewart Goldman    312-227-4844       Principal Investigator: Stewart Goldman          Children's Memorial Outpatient Center in Lincoln Park Active, not recruiting Chicago, Illinois, United States, 60614 United States, Maryland National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: Katherine E. Warren    301-435-4683    warrenk@mail.nih.gov    Principal Investigator: Katherine E. Warren          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira J. Dunkel    212-639-2153       Principal Investigator: Ira J. Dunkel          United States, North Carolina Duke University Medical Center Active, not recruiting Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Mariko D. DeWire-Schottmiller    513-803-1126       Principal Investigator: Mariko D. DeWire-Schottmiller          United States, Pennsylvania Children's Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Ian F. Pollack    412-692-5881       Principal Investigator: Ian F. Pollack          United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Giles W. Robinson    901-595-2907       Principal Investigator: Giles W. Robinson          United States, Texas Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Active, not recruiting Houston, Texas, United States, 77030 Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia A. Baxter    832-824-4681       Principal Investigator: Patricia A. Baxter Less <<
NCT02063230 Solid Tumors Phase 1 Completed - United States, Florida ... More >> Research Site Orlando, Florida, United States Less <<
NCT01011933 Endometrial Adenocarcinoma ... More >> Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma Recurrent Uterine Corpus Carcinoma Less << Phase 2 Completed - -
NCT00559949 Recurrent Thyroid Gland Carcin... More >>oma Stage I Thyroid Gland Papillary Carcinoma Stage II Thyroid Gland Papillary Carcinoma Stage III Thyroid Gland Papillary Carcinoma Stage IV Thyroid Gland Papillary Carcinoma Less << Phase 2 Completed - United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT02393690 Metastatic Thyroid Gland Carci... More >>noma Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 Less << Phase 2 Recruiting August 1, 2020 United States, California ... More >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Gerald Henderson    858-822-5223    gehenderson@ucsd.edu    Principal Investigator: Gregory A. Daniels          Hoag Memorial Hospital Recruiting Newport Beach, California, United States, 92663 Contact: Atessa Kiani    919-764-6586    atessa.kiani@hoag.org    Principal Investigator: Michael J. Demeure          United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Paula Fisk    720-848-0676    paula.fisk@ucdenver.edu    Principal Investigator: Bryan R. Haugen          United States, District of Columbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Lynette Wray    202-877-2749    lynette.wray@medstar.net    Principal Investigator: Kenneth D. Burman          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Lisa Freehafer    617-643-1751    lfreehafer@partners.org    Principal Investigator: Lori J. Wirth          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mabel Ryder    855-776-0015    Ryder.Mabel@mayo.edu    Principal Investigator: Mabel Ryder          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Jamie S. Walters    646-888-4450    waltersj@mskcc.org    Principal Investigator: Alan L. Ho          United States, North Carolina Duke University Medical Center Withdrawn Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Mamdouh Beshara    614-292-4511    Mamdouh.Beshara@osumc.edu    Principal Investigator: Jennifer A. Sipos          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Debra J. Nichols    713-792-0839    djnichols@mdanderson.org    Principal Investigator: Ramona Dadu Less <<
NCT02063230 - Completed - -
NCT03581487 Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IV Lung Cancer Stage IVA Lung Cancer Stage IVB Lung Cancer Less << Phase 1 Phase 2 Not yet recruiting April 16, 2020 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact       dlgibbon@mdanderson.org Less <<
NCT02407405 Neurofibromatosis 1 (NF1)|Plex... More >>iform Neurofibromas (PN) Less << PHASE2 ACTIVE_NOT_RECRUITING 2030-01-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT00559949 - Completed - -
NCT00588809 Adult Acute Myeloid Leukemia W... More >>ith t(15;17)(q22;q12) Adult Acute Promyelocytic Leukemia (M3) Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Less << Phase 2 Completed - United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 Less <<
NCT01635023 Healthy Volunteers Phase 1 Completed - United States, Kansas ... More >> Reseatch Site Overland Park, Kansas, United States Less <<
NCT01061749 Adult Solid Neoplasm Phase 1 Completed - United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Less <<
NCT00588809 - Completed - -
NCT00888134 Adult Solid Neoplasm PHASE2 COMPLETED 2025-01-15 Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Charlestown, Massachusetts, 02129, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States Less <<
NCT00888134 Adult Solid Neoplasm PHASE2 COMPLETED 2025-01-15 Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Charlestown, Massachusetts, 02129, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States Less <<
NCT01085214 - Completed - -
NCT01605916 Neoplasms,|Metastatic Cancer,|... More >>Non-Small Cell Lung Cancer|Advanced Solid Malignancies Less << PHASE1 COMPLETED 2025-05-15 Research Site, Fukuoka-shi, Ja... More >>pan|Research Site, Kashiwa-shi, Japan|Research Site, Nagoya-shi, Japan Less <<
NCT01085214 Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << Phase 2 Completed - United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892 National Institutes of Health Bethesda, Maryland, United States, 20892 United States, Montana Billings Clinic Cancer Center Billings, Montana, United States, 59107 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT02056392 - Completed - -
NCT03109301 Neoplasms, Nerve Tissue ... More >> Neurofibromatosis 1 Heredodegenerative Disorders, Nervous System Peripheral Nervous System Diseases Less << Phase 2 Recruiting February 1, 2023 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT01809210 Locally Advanced or Metastatic... More >> NSCL Cancer Stage IIIB IV Less << Phase 1 Completed - United Kingdom ... More >> Research Site Glasgow, United Kingdom, G12 0YN Research Site London, United Kingdom, W1G 6AD Research Site Manchester, United Kingdom, M20 4BX Research Site Newcastle upon Tyne, United Kingdom, NE7 7DN Less <<
NCT01843062 Differentiated Thyroid Cancer Phase 3 Active, not recruiting April 29, 2019 -
NCT01146756 Non Small Cell Lung Cancer PHASE1 COMPLETED 2017-02-08 The Christie NHS Foundation Tr... More >>ust, Manchester, Greater Manchester, M20 4BX, United Kingdom Less <<
NCT01783197 Non Small Cell Lung Cancer Phase 1 Active, not recruiting December 2018 Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 Ottawa Hospital Research Institute Ottawa, Ontario, Canada, K1H 8L6 Less <<
NCT01278615 Recurrent Adult Diffuse Large ... More >>Cell Lymphoma Less << Phase 2 Terminated(Closed Prematurely.... More >>) Less << - United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States, 60201 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 Southern Illinois University Springfield, Illinois, United States, 62702 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne, Indiana, United States, 46845 Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Massachusetts Tufts Medical Center Boston, Massachusetts, United States, 02111 University of Massachusetts Memorial Health Care Worcester, Massachusetts, United States, 01605 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Missouri Saint John's Mercy Medical Center Saint Louis, Missouri, United States, 63141 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10065 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02093728 Solid Tumours Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT01278615 - Terminated(Closed Prematurely.... More >>) Less << - -
NCT01809210 - Completed - -
NCT02448290 Gastric Adenocarcinoma Phase 2 Recruiting October 2018 Korea, Republic of ... More >> Samsung Medical center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Yoonjeong Ahn    82-2-2148-7395    younjeong.ahn@samsung.com    Principal Investigator: Jeeyun Lee, MD,PhD Less <<
NCT03004105 Malignant Neoplasm of Respirat... More >>ory and Intrathoracic Organ Carcinoma Advanced Lung Cancer Recurrent Nonsmall Cell Lung Cancer Less << Phase 2 Withdrawn(Inadequate funding) May 2024 -
NCT01242605 Biliary Tract Neoplasms ... More >> Cholangiocarcinoma Gallbladder Neoplasms Less << Phase 1 Completed - United Kingdom ... More >> Hammersmith Hospital London, United Kingdom University College London Hospital London, United Kingdom The Christie Hospital Manchester, United Kingdom Less <<
NCT02056392 Solid Tumours Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT02188264 Recurrent Colorectal Carcinoma... More >> Solid Neoplasm Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less << Phase 1 Active, not recruiting - United States, California ... More >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Colorado University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Missouri Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT03095248 Neurofibromatosis 2|Vestibular... More >> Schwannoma|Meningioma|Ependymoma|Glioma Less << PHASE2 COMPLETED 2024-05-21 Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT01949870 Inoperable Locally Advanced or... More >> Metastatic Biliary Tract Cancer Less << Phase 1 Terminated(change in the devel... More >>opment strategy) Less << - Japan ... More >> AZD6244 PhI Japanese Gem/ Kashiwa Shi, Chiba, Japan AZD6244 PhI Japanese Gem/ Chuo Ku, Tokyo, Japan Less <<
NCT02025114 Non-small Cell Lung Cancer (NS... More >>CLC) Less << Phase 1 Phase 2 Completed - Taiwan ... More >> National Cheng Kung University Hospital Tainan, Taiwan, 70403 Department of Oncology, National Taiwan University Hospital Taipei, Taiwan, 100 Taipei Veterans General Hospital Taipei, Taiwan, 11217 Less <<
NCT01974752 Metastatic Uv... More >>eal Melanoma Less << Phase 3 Completed - -
NCT01974752 - Completed - -
NCT03213691 Advanced Malignant Solid Neopl... More >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma BRAF Gene Mutation GNA11 Gene Mutation GNAQ Gene Mutation Histiocytosis HRAS Gene Mutation KRAS Gene Mutation NF1 Gene Mutation NRAS Gene Mutation Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Refractory Central Nervous System Neoplasm Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Less << Phase 2 Recruiting September 30, 2024 -
NCT02046850 Solid Tumours Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT02238782 Healthy Volunteers Bioavailabi... More >>lity Study Less << Phase 1 Completed - United Kingdom ... More >> Research Site Nottingham, United Kingdom Less <<
NCT02839720 Appearance Distress ... More >> Bothered by Itching Skin Cafe Au Lait Spot Cutaneous Neurofibroma Disfigurement Dysplasia Lisch Nodule Neurofibromatosis Type 1 NF1 Gene Mutation Optic Nerve Glioma Less << Phase 2 Recruiting December 31, 2018 United States, Alabama ... More >> University of Alabama at Birmingham Cancer Center Recruiting Birmingham, Alabama, United States, 35233 Contact: Bruce R. Korf    205-934-9411    bkorf@uabmc.edu    Principal Investigator: Bruce R. Korf          United States, Maryland National Institutes of Health Clinical Center Not yet recruiting Bethesda, Maryland, United States, 20892 Contact: Brigitte C. Widemann    301-496-0738 ext 7    widemanb@mail.nih.gov    Principal Investigator: Brigitte C. Widemann          United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Not yet recruiting Dallas, Texas, United States, 75390 Contact: Lu Q. Le    214-648-7097    lu.le@utsouthwestern.edu    Principal Investigator: Lu Q. Le Less <<
NCT02238782 - Completed - -
NCT02063204 Solid Tumours Phase 1 Completed - United States, Florida ... More >> Research Site Orlando, Florida, United States Less <<
NCT02322749 Healthy Volunteers Bioequivale... More >>nce or Bioavailability Study Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT03392246 Non-small Cell Lung Cancer Phase 2 Recruiting June 30, 2025 United States, Massachusetts ... More >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zofia Piotrowska, MD       zpiotrowska@partners.org    Principal Investigator: Zofia Piotrowska, MD          Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Daniel Costa, MD       dbcosta@bidmc.harvard.edu    Principal Investigator: Daniel Costa, MD          Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sarah E Clifford    617-632-5438    SarahE_Clifford@DFCI.HARVARD.EDU    Principal Investigator: Pasi A Janne, MD Less <<
NCT02322749 - Completed - -
NCT01960374 Healthy Volunteers Pharmacokin... More >>etic Study Less << PHASE1 COMPLETED 2025-05-14 Research Site, London, United ... More >>Kingdom Less <<
NCT01931761 Solid Tumours Phase 1 Completed - United Kingdom ... More >> Research Site Ruddington, United Kingdom Less <<
NCT02583542 Triple-Negative Breast Cancer ... More >> Squamous Cell Lung Cancer Non-squamous Cell Lung Cancer With KRAS Mutations Non-squamous Cell Lung Cancer With Wild-type KRAS Less << Phase 1 Phase 2 Recruiting July 2019 United Kingdom ... More >> University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom, B15 2TT Contact: Gary Middleton, Professor    +44 (0) 1213713573    Gary.Middleton@uhb.nhs.uk    Contact: Ceri Amstrong    +44 (0) 1214143795    c.j.armstrong@bham.ac.uk    Principal Investigator: Gary Middleton, Professor          Barts Health NHS Trust Recruiting London, United Kingdom, EC1M 6BQ Contact: Peter Schmid    +44 (0)20 7882 8498    p.schmid@qmul.ac.uk    Contact: Louise Lim       farahlouise.lim@bartshealth.nhs.uk    Principal Investigator: Peter Schmid          Sub-Investigator: Louise Lim          University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, W1T 7HA Contact: Martin Forster, Dr    +44 (0) 2034475085    Martin.Forster@uclh.nhs.uk    Contact: Magda Rocha    +44 (0) 2034472921    Magda.PintoRocha@uclh.nhs.uk    Principal Investigator: Martin Forster, Dr          Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Yvonne Summers, Dr    +44 (0) 161 446 8016    yvonne.summers@christie.nhs.uk    Contact: Rachael Finney    +44 (0) 1619182318    rachael.finney@christie.nhs.uk    Principal Investigator: Yvonne Summers, Dr Less <<
NCT03040986 KRAS NP_004976.2:p.G12R ... More >> Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Less << Phase 2 Suspended(Interim monitoring) December 31, 2021 United States, California ... More >> Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Maryland NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT01949870 - Terminated(change in the devel... More >>opment strategy) Less << - -
NCT01974349 Solid Tumours Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT03162627 Malignant Neoplasm of Breast ... More >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Male Genital Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands Less << Phase 1 Recruiting August 2026 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       swestin@mdanderson.org Less <<
NCT03705507 Acute Lymphoblastic Leukemia ... More >> Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia Recurrent Less << Phase 1 Phase 2 Recruiting March 17, 2021 United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom Principal Investigator: Alice Norton          Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom Principal Investigator: Mark Caswell          Department of Paediatric Oncology, Royal Marsden Hospital, Sutton Recruiting London Borough of Sutton, United Kingdom Principal Investigator: Donna Lancaster          Haemato-Oncology Adult Unit, Royal Marsden Hospital, Sutton Recruiting London Borough of Sutton, United Kingdom Sub-Investigator: David Taussig          University College Hospital Recruiting London, United Kingdom Principal Investigator: Adele Fielding          The Christie Hospital Recruiting Manchester, United Kingdom Principal Investigator: Anna Castleton          Freeman Hospital Recruiting Newcastle, United Kingdom Sub-Investigator: Tobias Menne          Great North Children's Hospital, Royal Victoria Infirmary Recruiting Newcastle, United Kingdom Principal Investigator: Geoff Shenton Less <<
NCT01752569 AIDS-related Kaposi's Sarcoma PHASE1|PHASE2 TERMINATED 2017-12-20 Brighton and Sussex University... More >> Hospitals, Brighton, BN2 5BE, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Free Hospital, London, NW3 2QG, United Kingdom|Chelsea & Westminster Hospital, London, SW10 9NH, United Kingdom|The Christie Hospital, Manchester, M20 4BX, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2SJ, United Kingdom Less <<
NCT03745989 Solid Tumors Phase 1 Not yet recruiting May 6, 2022 -
NCT03433183 Malignant Peripheral Nerve She... More >>ath Tumors Neurofibromatosis 1 Less << Phase 2 Not yet recruiting September 2021 -
NCT03326388 Neurofibromatosis Type 1|Plexi... More >>form Neurofibroma|Optic Nerve Glioma Less << PHASE1|PHASE2 COMPLETED 2024-02-14 Great Ormond Street Hospital f... More >>or Children NHS Foundation Trust, London, wc1n 1eh, United Kingdom|Great Ormond Street Hospital NHS Foundatin Trust, London, WC1N 3JH, United Kingdom Less <<
NCT02768766 Uveal Melanoma Phase 1 Recruiting January 2019 United States, New York ... More >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Richard Carvajal, MD       rdc2150@cumc.columbia.edu    Principal Investigator: Richard Carvajal, MD          Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alexander N Shoushtari, M.D    646-888-4161    shoushta@mskcc.org    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Sapna Patel, M.D    713-792-4955    sppatel@mdanderson.org Less <<
NCT03326310 Chronic Myeloid Leukemia ... More >> Myelofibroses Less << Phase 1 Recruiting September 4, 2023 United States, Illinois ... More >> The University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Melissa Fridstein    773-702-9885    mfridstein@medicine.bsd.uchicago.edu Less <<
NCT02450656 Colorectal Neoplasms ... More >> Gastrointestinal Neoplasms Pancreatic Neoplasms Carcinoma, Non-Small-Cell Lung Less << Phase 1 Phase 2 Recruiting December 2019 Netherlands ... More >> UMC St. Radboud Nijmegen Recruiting Nijmegen, Gelderland, Netherlands, 6525GA Contact: Carla ML van Herpen, MD, PhD    +31243610353    Carla.vanHerpen@radboudumc.nl    Principal Investigator: Carla ML van Herpen, MD, PhD          Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: F Opdam, MD, PhD          Principal Investigator: F Opdam, MD, PhD Less <<
NCT04495127 Neurofibromatosis Type 1 PHASE1 COMPLETED 2023-03-24 Research Site, Minato-ku, 105-... More >>8471, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Setagaya-ku, 157-8535, Japan Less <<
NCT05253131 MPNST|NF1|Sarcoma PHASE2 NOT_YET_RECRUITING 2031-06-15 The University of Alabama at B... More >>irmingham, Birmingham, Alabama, 35294, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University, Indianapolis, Indiana, 46202, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|National Cancer Institute (NCI), Bethesda, Maryland, 20892, United States|Mayo Clinic, Minneapolis, Minnesota, 56001, United States|Washington University - St. Louis, Saint Louis, Missouri, 63110, United States|New York University Medical Center, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19096, United States|Childrens Medical Center - Univ. of Texas SW, Dallas, Texas, 75235, United States Less <<
NCT06621082 Neurofibromatosis 1 PHASE2 NOT_YET_RECRUITING 2026-12-31 -
NCT06620354 Neurofibromatosis 1 PHASE2 NOT_YET_RECRUITING 2026-12-31 -
NCT06763315 Plexiform Neurofibromas (PN) PHASE2 NOT_YET_RECRUITING 2028-10-31 West China Hospital of Sichuan... More >> University, Chengdu, Sichuan, 610041, China Less <<
NCT05101148 Neurofibromatosis Type 1 PHASE1 ACTIVE_NOT_RECRUITING 2026-01-12 Research Site, Rochester, Minn... More >>esota, 55905, United States|Research Site, Akron, Ohio, 44308, United States|Research Site, Bydgoszcz, 85-094, Poland|Research Site, Gdańsk, 80-952, Poland|Research Site, Warszawa, 02-091, Poland|Research Site, Moscow, 119620, Russian Federation|Research Site, Moscow, 125412, Russian Federation|Research Site, Barcelona, 08950, Spain|Research Site, Madrid, 28009, Spain Less <<
NCT04590235 Neurofibromatosis 1|Neurofibro... More >>ma Plexiform Less << PHASE1 ACTIVE_NOT_RECRUITING 2026-08-31 Research Site, Shanghai, 20001... More >>1, China|Research Site, Shanghai, CN-200092, China Less <<
NCT06188741 Neurofibromatosis 1|Plexiform ... More >>Neurofibroma Less << PHASE2 NOT_YET_RECRUITING 2032-03-01 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.92mL

2.18mL

1.09mL

21.85mL

4.37mL

2.18mL

References

 

Historical Records

Categories